-
1
-
-
0032843176
-
Adjuvant systemic therapy for primary breast cancer
-
F.J. Esteva, and G.N. Hortobagyi Adjuvant systemic therapy for primary breast cancer Surg. Clin. N. Am. 79 1999 1075 1090
-
(1999)
Surg. Clin. N. Am.
, vol.79
, pp. 1075-1090
-
-
Esteva, F.J.1
Hortobagyi, G.N.2
-
2
-
-
0036798273
-
Molecular prognostic factors for breast cancer metastasis and survival
-
F.J. Esteva, A.A. Sahin, and M. Cristofanilli Molecular prognostic factors for breast cancer metastasis and survival Semin. Radiat. Oncol. 12 2002 319 328
-
(2002)
Semin. Radiat. Oncol.
, vol.12
, pp. 319-328
-
-
Esteva, F.J.1
Sahin, A.A.2
Cristofanilli, M.3
-
3
-
-
0031732731
-
Integration of systemic chemotherapy in the management of primary breast cancer
-
F.J. Esteva, and G.N. Hortobagyi Integration of systemic chemotherapy in the management of primary breast cancer Oncologist 3 1998 1 14
-
(1998)
Oncologist
, vol.3
, pp. 1-14
-
-
Esteva, F.J.1
Hortobagyi, G.N.2
-
4
-
-
0032896905
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for prediction response to adjuvant endocrine therapy in breast cancer
-
J.M. Harvey, G.M. Clark, and C.K. Osborne Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for prediction response to adjuvant endocrine therapy in breast cancer J. Clin. Oncol. 17 1999 1474 1481
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1474-1481
-
-
Harvey, J.M.1
Clark, G.M.2
Osborne, C.K.3
-
5
-
-
0026650016
-
Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
-
S. Toikkanen, H. Helin, and J. Isola Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up J. Clin. Oncol. 10 1992 1044 1048
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 1044-1048
-
-
Toikkanen, S.1
Helin, H.2
Isola, J.3
-
6
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
M.A. Cobleigh, C.L. Vogel, and D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J. Clin. Oncol. 17 1999 2639 2648
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
7
-
-
0024651788
-
Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32
-
N.C. Popescu, C.R. King, and M.H. Kraus Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32 Genomics 4 1989 362 366
-
(1989)
Genomics
, vol.4
, pp. 362-366
-
-
Popescu, N.C.1
King, C.R.2
Kraus, M.H.3
-
8
-
-
0042208398
-
The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
-
J.S. Ross, J.A. Fletcher, and G.P. Linette The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 2003 307 325
-
(2003)
Oncologist
, vol.8
, pp. 307-325
-
-
Ross, J.S.1
Fletcher, J.A.2
Linette, G.P.3
-
9
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
-
D.J. Slamon, G.M. Clark, and S.C. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 1987 177 182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.C.3
-
11
-
-
0012890297
-
HER2 testing and correlation with efficacy of Trastuzumab therapy
-
M. Fornier, M. Risio, and C. Van Poznak HER2 testing and correlation with efficacy of Trastuzumab therapy Oncology 16 2002 1340 1352
-
(2002)
Oncology
, vol.16
, pp. 1340-1352
-
-
Fornier, M.1
Risio, M.2
Van Poznak, C.3
-
12
-
-
0035189256
-
Current status of HER2 testing: Caught between a rock and a hard place
-
S.J. Schnitt, and T.W. Jacobs Current status of HER2 testing: caught between a rock and a hard place Am. J. Clin. Pathol. 116 2001 806 810
-
(2001)
Am. J. Clin. Pathol.
, vol.116
, pp. 806-810
-
-
Schnitt, S.J.1
Jacobs, T.W.2
-
13
-
-
0035496541
-
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis
-
S.A. Eccles The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis J. Mammary Gland Biol. Neoplasia 6 2001 393 406
-
(2001)
J. Mammary Gland Biol. Neoplasia
, vol.6
, pp. 393-406
-
-
Eccles, S.A.1
-
14
-
-
0034766736
-
Biology of HER2 and its importance in breast cancer
-
Y. Yarden Biology of HER2 and its importance in breast cancer Oncology 61 Suppl. 2 2001 1 13
-
(2001)
Oncology
, vol.61
, Issue.SUPPL. 2
, pp. 1-13
-
-
Yarden, Y.1
-
16
-
-
0035873962
-
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
-
R.R. Tubbs, J.D. Pettay, and P.C. Roche Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J. Clin. Oncol. 19 2001 2714 2721
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 2714-2721
-
-
Tubbs, R.R.1
Pettay, J.D.2
Roche, P.C.3
-
17
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
18
-
-
1842614241
-
Docetaxel combined with Trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial
-
K.L. Tedesco, A.D. Thor, and D.H. Johnson Docetaxel combined with Trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial J. Clin. Oncol. 22 2004 1071 1077
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 1071-1077
-
-
Tedesco, K.L.1
Thor, A.D.2
Johnson, D.H.3
-
19
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
C.L. Vogel, M.A. Cobleigh, and D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
20
-
-
0035868668
-
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
-
R.C. Bast, J.P. Ravdin, and D.F. Hayes 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 19 2001 1865 1878
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1865-1878
-
-
Bast, R.C.1
Ravdin, J.P.2
Hayes, D.F.3
-
21
-
-
0344453811
-
The clinical evaluation of HER2 status: Which test to use?
-
J. Bartlett, E. Mallon, and T. Cooke The clinical evaluation of HER2 status: which test to use? J. Pathol. 199 2003 411 417
-
(2003)
J. Pathol.
, vol.199
, pp. 411-417
-
-
Bartlett, J.1
Mallon, E.2
Cooke, T.3
-
22
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
D.J. Slamon, W. Godolphin, and L. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.3
-
23
-
-
0037384049
-
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
-
M. Dowsett, J. Bartlett, and J.O. Ellis Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J. Pathol. 199 2003 418 423
-
(2003)
J. Pathol.
, vol.199
, pp. 418-423
-
-
Dowsett, M.1
Bartlett, J.2
Ellis, J.O.3
-
24
-
-
0037099732
-
Evaluation of HER2 gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
-
M.F. Press, D.J. Slamon, and K.J. Flom Evaluation of HER2 gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J. Clin. Oncol. 20 2002 3095 3105
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 3095-3105
-
-
Press, M.F.1
Slamon, D.J.2
Flom, K.J.3
-
25
-
-
0037325177
-
Current perspectives on HER2 testing: A review of national testing guidelines
-
M. Bilous, M. Dowsett, and W. Hanna Current perspectives on HER2 testing: a review of national testing guidelines Mod. Pathol. 16 2003 173 182
-
(2003)
Mod. Pathol.
, vol.16
, pp. 173-182
-
-
Bilous, M.1
Dowsett, M.2
Hanna, W.3
-
26
-
-
0033871534
-
HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
-
R.L. Ridolfi, M.R. Jamehdor, and J.M. Arber HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Mod. Pathol. 13 2000 866 873
-
(2000)
Mod. Pathol.
, vol.13
, pp. 866-873
-
-
Ridolfi, R.L.1
Jamehdor, M.R.2
Arber, J.M.3
-
27
-
-
2142758687
-
HER-2 testing in breast cancer using parallel tissue-based methods
-
H. Yaziji, L.C. Goldstein, and T.S. Barry HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 2004 1972 1977
-
(2004)
JAMA
, vol.291
, pp. 1972-1977
-
-
Yaziji, H.1
Goldstein, L.C.2
Barry, T.S.3
-
28
-
-
0037024478
-
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
-
P.C. Roche, V.J. Suman, and R.B. Jenkins Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J. Natl. Cancer Inst. 94 2002 855 857
-
(2002)
J. Natl. Cancer Inst.
, vol.94
, pp. 855-857
-
-
Roche, P.C.1
Suman, V.J.2
Jenkins, R.B.3
-
29
-
-
0037023986
-
Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience
-
S. Paik, J. Bryant, E. Tan-Chiu, and E. Romond Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience J. Natl. Cancer Inst. 94 2002 852 854
-
(2002)
J. Natl. Cancer Inst.
, vol.94
, pp. 852-854
-
-
Paik, S.1
Bryant, J.2
Tan-Chiu, E.3
Romond, E.4
-
30
-
-
0028221475
-
Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
-
F. Penault-Llorca, J. Adelaide, and G. Houvenaeghel Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation J. Pathol. 173 1994 65 75
-
(1994)
J. Pathol.
, vol.173
, pp. 65-75
-
-
Penault-Llorca, F.1
Adelaide, J.2
Houvenaeghel, G.3
-
31
-
-
0028641571
-
C-erB-2 immunostaining: Problems with interpretation
-
E.W. Kay, C.J. Walsh, and M. Cassidy C-erB-2 immunostaining: problems with interpretation J. Clin. Pathol. 47 1994 816 822
-
(1994)
J. Clin. Pathol.
, vol.47
, pp. 816-822
-
-
Kay, E.W.1
Walsh, C.J.2
Cassidy, M.3
-
32
-
-
0038078174
-
Conference summary, strategic science symposium: HER-2/neu testing of breast cancer patients in clinical practice
-
R.J. Zarbo, and E.H. Hammond Conference summary, strategic science symposium: HER-2/neu testing of breast cancer patients in clinical practice Arch. Pathol. Lab. Med. 127 2003 549 553
-
(2003)
Arch. Pathol. Lab. Med.
, vol.127
, pp. 549-553
-
-
Zarbo, R.J.1
Hammond, E.H.2
-
33
-
-
0036314362
-
Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing
-
Cell Markers and Cytogenetics Committees College of American Pathologists Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing Arch. Pathol. Lab. Med. 126 2002 803 808
-
(2002)
Arch. Pathol. Lab. Med.
, vol.126
, pp. 803-808
-
-
-
34
-
-
0034327895
-
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
-
G. Pauletti, S. Dandekar, and H. Rong Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J. Clin. Oncol. 18 2000 3651 3664
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3651-3664
-
-
Pauletti, G.1
Dandekar, S.2
Rong, H.3
-
35
-
-
0036161321
-
HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
-
E.A. Perez, P.C. Roche, and R.B. Jenkins HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin. Proc. 77 2002 148 154
-
(2002)
Mayo Clin. Proc.
, vol.77
, pp. 148-154
-
-
Perez, E.A.1
Roche, P.C.2
Jenkins, R.B.3
-
36
-
-
0002860255
-
Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH)
-
R.D. Mass, M. Press, and S. Anderson Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract 85] Proc. Am. Soc. Clin. Oncol. 20 2001 22a
-
(2001)
Proc. Am. Soc. Clin. Oncol.
, vol.20
-
-
Mass, R.D.1
Press, M.2
Anderson, S.3
-
37
-
-
2342545547
-
Fluorescence in situ hybridization
-
J.M.S. Bartlett Fluorescence in situ hybridization Methods Mol. Med. 97 2004 77 87
-
(2004)
Methods Mol. Med.
, vol.97
, pp. 77-87
-
-
Bartlett, J.M.S.1
-
38
-
-
0034018946
-
Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays
-
S. Wang, M.H. Saboorian, and E.P. Frenkel Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays J. Clin. Pathol. 53 2000 374 381
-
(2000)
J. Clin. Pathol.
, vol.53
, pp. 374-381
-
-
Wang, S.1
Saboorian, M.H.2
Frenkel, E.P.3
-
39
-
-
2042467574
-
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring
-
P. Lal, P.A. Salazar, and C.A. Hudis HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring Am. J. Clin. Pathol. 121 2004 631 636
-
(2004)
Am. J. Clin. Pathol.
, vol.121
, pp. 631-636
-
-
Lal, P.1
Salazar, P.A.2
Hudis, C.A.3
-
40
-
-
4844228676
-
Comparative assays for the HER-2/neu oncogene status in breast cancer
-
J.M. Vera-Roman, and L.A. Rubio-Martinez Comparative assays for the HER-2/neu oncogene status in breast cancer Arch. Pathol. Lab. Med. 128 2004 627 633
-
(2004)
Arch. Pathol. Lab. Med.
, vol.128
, pp. 627-633
-
-
Vera-Roman, J.M.1
Rubio-Martinez, L.A.2
-
41
-
-
85059046809
-
The influence of polysomy 17 (CEP17+) on HER2 protein expression in carcinoma of the breast
-
E. Downs-Kelly, M. Stoler, and R. Tubbs The influence of polysomy 17 (CEP17+) on HER2 protein expression in carcinoma of the breast Mod. Pathol. 17 2004 29A
-
(2004)
Mod. Pathol.
, vol.17
-
-
Downs-Kelly, E.1
Stoler, M.2
Tubbs, R.3
-
42
-
-
0036183416
-
Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implications for clinical assessment of HER-2/neu status
-
S. Wang, H. Saboorian, and E.P. Frenkel Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implications for clinical assessment of HER-2/neu status Mod. Pathol. 15 2002 137 145
-
(2002)
Mod. Pathol.
, vol.15
, pp. 137-145
-
-
Wang, S.1
Saboorian, H.2
Frenkel, E.P.3
-
44
-
-
0033932514
-
Effects of formalin tissue fixation and processing on immunohistochemistry
-
M. Werner, A. Chott, and A. Fabiano Effects of formalin tissue fixation and processing on immunohistochemistry Am. J. Surg. Pathol. 24 2000 1016 1019
-
(2000)
Am. J. Surg. Pathol.
, vol.24
, pp. 1016-1019
-
-
Werner, M.1
Chott, A.2
Fabiano, A.3
-
45
-
-
0346125406
-
TOP2A and HER-2 amplification in fine needle aspirates from breast cancer
-
A.M. Bofin, B. Ytterhus, and B.M. Hagmar TOP2A and HER-2 amplification in fine needle aspirates from breast cancer Cytopathology 14 2003 314 319
-
(2003)
Cytopathology
, vol.14
, pp. 314-319
-
-
Bofin, A.M.1
Ytterhus, B.2
Hagmar, B.M.3
-
46
-
-
0031777591
-
Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
-
J.M. Bartlett, A.D. Watters, and S.A. Ballantyne Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br. J. Cancer 77 1998 2193 2198
-
(1998)
Br. J. Cancer
, vol.77
, pp. 2193-2198
-
-
Bartlett, J.M.1
Watters, A.D.2
Ballantyne, S.A.3
-
47
-
-
0032729607
-
Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy
-
J.M.S. Bartlett, L. Adie, and A.D. Watters Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy BJU Int. 84 1999 775 779
-
(1999)
BJU Int.
, vol.84
, pp. 775-779
-
-
Bartlett, J.M.S.1
Adie, L.2
Watters, A.D.3
-
48
-
-
0033984977
-
Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder
-
A.D. Watters, S.A. Ballantyne, and J.J. Going Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder BJU Int. 85 2000 42 47
-
(2000)
BJU Int.
, vol.85
, pp. 42-47
-
-
Watters, A.D.1
Ballantyne, S.A.2
Going, J.J.3
-
49
-
-
0035162262
-
Evaluating HER2 amplification and overexpression in breast cancer
-
J.M.S. Bartlett, J. Reeves, and P. Stanton Evaluating HER2 amplification and overexpression in breast cancer J. Pathol. 195 2001 422 428
-
(2001)
J. Pathol.
, vol.195
, pp. 422-428
-
-
Bartlett, J.M.S.1
Reeves, J.2
Stanton, P.3
-
51
-
-
2142660746
-
High-quality HER2 testing: Setting a standard for oncologic biomarker assessment
-
E.L. Wiley, and L.K. Diaz High-quality HER2 testing: setting a standard for oncologic biomarker assessment JAMA 291 2004 1972 1973
-
(2004)
JAMA
, vol.291
, pp. 1972-1973
-
-
Wiley, E.L.1
Diaz, L.K.2
-
52
-
-
0036314362
-
Clinical laboratory assays for Her2/neu amplification and overexpression; Quality assurance, standardization, and proficiency testing
-
R. Nagle, R. Tubbs, and P. Roche Clinical laboratory assays for Her2/neu amplification and overexpression; quality assurance, standardization, and proficiency testing Arch. Pathol. Lab. Med. 126 2002 803 808
-
(2002)
Arch. Pathol. Lab. Med.
, vol.126
, pp. 803-808
-
-
Nagle, R.1
Tubbs, R.2
Roche, P.3
-
53
-
-
0036094229
-
Gold-facilitated in situ hybridization: A bright field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification
-
R. Tubbs, J. Pettay, and M. Skacel Gold-facilitated in situ hybridization: a bright field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification Am. J. Pathol. 160 2002 1589 1595
-
(2002)
Am. J. Pathol.
, vol.160
, pp. 1589-1595
-
-
Tubbs, R.1
Pettay, J.2
Skacel, M.3
-
54
-
-
0033694650
-
Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
-
M. Tanner, D. Gancberg, and A. Di Leo Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am. J. Pathol. 157 2000 1467 1472
-
(2000)
Am. J. Pathol.
, vol.157
, pp. 1467-1472
-
-
Tanner, M.1
Gancberg, D.2
Di Leo, A.3
|